Chlorhexidine + Ophytrium

Verify with FDA CVM →

149 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
149
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

ChlorhexidineOphytrium

Administration Routes

TopicalUnknown

Species Affected

Dog 134
Cat 10
Human 5

Most Affected Breeds

Crossbred Canine/dog 30
Dog (unknown) 16
Retriever - Labrador 9
Unknown 8
Pit Bull 7
Maltese 7
Domestic Shorthair 6
Mixed (Dog) 5
Shih Tzu 4
Terrier - Boston 4

Most Reported Reactions

Application site erythema 53
Application site pain 18
Application site pruritus 16
Application site inflammation 16
Application site reddening 14
Lack of efficacy - NOS 10
Vocalisation 9
Application site irritation 9
Licking at application site 7
Application site scab 6
Lethargy (see also Central nervous system depression in Neurological) 6
Application site crust 6

Outcome Breakdown

Ongoing
69 (46.3%)
Recovered/Normal
59 (39.6%)
Outcome Unknown
21 (14.1%)

Data Summary

Metric Value
Total adverse event reports 149
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 2

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Chlorhexidine + Ophytrium Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 149 adverse event reports referencing Chlorhexidine + Ophytrium, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Chlorhexidine, Ophytrium. Reported administration routes include Topical, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Chlorhexidine + Ophytrium reports are Dog (134 reports), Cat (10 reports), Human (5 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (30), Dog (unknown) (16), Retriever - Labrador (9) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Chlorhexidine + Ophytrium are Application site erythema (53), Application site pain (18), Application site pruritus (16), Application site inflammation (16). Of the 149 reports with a coded outcome, Ongoing is the leading category at 46.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Chlorhexidine + Ophytrium.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial